Prostate cancer is one of the most common cancers in men and poses a significant threat to global male health. Traditional prostate cancer assessment methods have certain limitations, necessitating the identification of new prognostic factors and treatment targets. Our study revealed that low expression of the cornichon family AMPA receptor auxiliary protein 2 (CNIH2) gene was associated with a better progression-free survival rate in prostate cancer patients. The area under the receiver operating characteristic (ROC) curve (AUC) showed that the prognostic ability of the CNIH2 gene was high at 1, 3, and 5 years. The gene was an independent prognostic factor according to multivariate analysis. Functional verification experiments showed that knocking down the CNIH2 gene could inhibit the proliferation, migration and invasion of prostate cancer cells and could also inhibit tumor growth in nude mice. Our study is the first to reveal the important role of the CNIH2 gene in prostate cancer. This discovery provides a new research direction for individualized treatment and prognostic evaluation of prostate cancer.
Background: Existing research has revealed that various factors, including environmental pollutants, can affect renal function. This study aims to explore the association between various synthetic Endocrine Disruptors(EDs), which are widely present in the environment, and the renal function of middle-aged and older adult populations.Methods: Based on data from the National Health and Nutrition Examination Survey (NHANES) from 2015 to 2018, a total of 1,199 participants, with a median age of 57 years, who had CKD or at least one CKD complication (such as dyslipidemia, hypertension, diabetes, or hyperuricemia), were included. A comprehensive assessment was conducted on the relationship between 28 synthetic EDs (including perfluoro/polyfluoroalkyl compounds, phosphorus-containing pesticides, and plasticizers) and renal function. Serum concentrations of synthetic EDs were determined using mass spectrometry. Renal function was assessed through urine Albumin-to-Creatinine Ratio (ACR) measurements. The quantile regression models were employed to explore the association between synthetic EDs and renal function. The grouped regression models were used to investigate the differential associations of synthetic EDs with non-CKD and CKD populations.Results: In this study, N-perfluorooctanoic acid, MECP phthalate, and Diethylthiophosphate were found to exert damaging effects on renal function. N-perfluorooctanoic acid and MECP phthalate were observed to exhibit differential associations with non-CKD and CKD populations. There was a significant difference in the effect of N-perfluorooctanoic acid between the non-CKD and CKD groups. N-perfluorooctanoic acid was not associated with renal function impairment in the non-CKD group, whereas it exhibited a significant adverse association in the CKD group. There was a significant difference in the effect of MECP phthalate between the non-CKD and CKD groups. MECP phthalate was associated with renal function impairment in the non-CKD group, but not in the CKD group.Conclusion: This study elucidates the associations and differences of synthetic EDs with renal function. Based on the findings, enhanced monitoring and health education regarding environmental exposure to synthetic EDs such as N-perfluorooctanoic acid, MECP phthalate, and Diethylthiophosphate can be implemented to reduce public exposure risks.
Rationale: Uro-originated epidermoid cysts, especially located in the upper urinary tract are rare and only 4 cases of epidermoid cyst occurring in the upper urinary tract have been reported worldwide so far. In the previous cases, the cysts were diagnosed as tumors and organs were removed. Patient concerns and diagnosis: We report a case of epidermoid cyst in ureter in a 48-year-old female patient admitted to the local hospital suffering from paroxysmal pain in the right hypochondriac for 8 years. Interventions and outcomes: She underwent right ureteroscopy in order to rule out the possibility of urinary epithelial carcinoma. The tumor was pathological diagnosed as a benign ureterocyst epidermoid. Postoperatively, the patient showed good recovery. During the 24-month follow-up period, the patient remained well and free of complications. Conclusion: This case illustrates that benign epidermoid cysts can appear in the ureter, although it is extremely rare. It also indicates that perioperative examinations must be exhaustive to avoid the further injury to the patients.
18 September 2024 in Expert Opinion on Drug Safety
BackgroundProstate cancer is one of the most common malignancies in men worldwide, and prostate-specific antigen (PSA) screening is widely used for its early detection. Drug use may affect PSA levels, but the effect for most drugs is currently unknown.MethodsThis study first investigated drugs related to PSA changes through the Food and Drug Administration Adverse Event Reporting System (FAERs) database, and then used a Mendelian randomization (MR) method to explore the causal relationship between specific drugs and PSA changes using a genome-wide association study (GWAS) data. The statistical analysis software SAS and R were used in the study.ResultsThrough analysis of the FAERs database, 22 drugs were found to be associated with an increase in PSA, and 14 drugs were associated with a decrease in PSA. MR analysis showed that the use of tamsulosin may lead to an increase in PSA. Heterogeneity test, horizontal pleiotropy test and leave-one-out Analysis verified the stability of the results. MR analyses for other drugs did not show statistical significance.ConclusionThis study provided a basis for better understanding the impact of medications on prostate health, helping to avoid overdiagnosis or underdiagnosis of high-risk patients. However, research still requires larger-scale validation and in-depth exploration.
Background: The purpose of our research was to discover the adverse events (AEs) not mentioned in the previous y drug instructions after using gemcitabine, so as to guide clinical medication. Methods: The Food and Drug Administration Adverse Event Reporting System (FAERS) database was utilized to retrieve AEs associated with the use of gemcitabine up to 2023. Four methods were used to detect new signals of adverse drug reactions(Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayesian Geometric Mean). AEs were considered positive signals only if they were detected by all four algorithms. Results: Between 2014 and 2023, 14,905 individuals experienced 42,360 AEs following the use of gemcitabine. totaling 437 preferred terms (PTs) distributed across 20 system organ classes (SOCs). We focused on AEs that were either not mentioned or mentioned less frequently in SOCs related to eye diseases, the nervous system, and the ear and labyrinth. After the administration of gemcitabine, patients exhibited retinopathy (Case number: 28), Purtscher retinopathy (Case number: 10), choroidal effusion (Case number: 9), amaurosis (Case number: 9), cystoid macular edema (Case number: 8), and other ocular organ system-related AEs. In terms of the nervous system, peripheral neuropathy (Case number: 363), neurotoxicity (Case number: 117), polyneuropathy (Case number: 92), and other neurologic AEs were observed. Furthermore, in the ear and labyrinth, ototoxicity (Case number: 9) was reported. Conclusion: Our study identified previously undetected AEs following treatment with gemcitabine, which may provide new insights for future medication guidance.